Ashish Upadhyay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ashish Upadhyay has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
Bertrand L. Jaber
Division of Nephrology, Department of Medicine, St. Elizabeth's Medical Center and Tufts University School of Medicine, Boston, Massachusetts
5 shared publicationsShih-Jen Hwang
Framingham Heart Study, National Heart, Lung, and Blood Institute, Framingham, Massachusetts; Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland
5 shared publications- Caroline S. Fox
NHLBI's Framingham Heart Study, Framingham, Massachusetts, USA
4 shared publications - Emelia J. Benjamin
Boston University Chobanian & Avedisian School of Medicine
3 shared publications James B. Meigs
General Medicine Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA
3 shared publications- Martin G. Larson
Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
3 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study
Sodium-glucose cotransporter 2 (SGLT2)-inhibitors are key in chronic kidney disease (CKD) management with empagliflozin and dapagliflozin being the two mos
- 11 June 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessEmpagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study
Sodium-glucose cotransporter 2 (SGLT2)-inhibitors are key in chronic kidney disease (CKD) management with empagliflozin and dapagliflozin being the two mos
- Open Access
- 19 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 2582-2593
Diabetic kidney disease, biomarkers, and finerenone
Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals with DKD. While the standard treatment approach incorporating renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduces the risk for kidney disease progression and CVD, the high residual risk that persists despite these treatments underscores the need for novel therapies for DKD. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), is a proven therapeutic option for DKD that targets inflammatory and fibrotic pathways involved in its progression. Furthermore, finerenone has been evaluated for DKD outcomes in phase 3 clinical trials, has a favourable side effect profile compared to steroidal MRAs, reduces the risks of major kidney and CVD outcomes in clinical trials when used with RAAS blockers, and is the only MRA specifically approved for DKD and recommended for DKD in treatment guidelines. The integration of novel biomarkers of CKD and CVD into the clinical management of DKD may improve early identification of at‐risk individuals and allow for patient‐specific therapeutic strategies. This review provides a brief overview of the pathogenesis of DKD and the role of mineralocorticoid receptor activation in DKD pathobiology, summarises the role of finerenone in the treatment paradigm of DKD, evaluates current and emerging biomarkers of DKD and finerenone's impact on these biomarkers, and provides forward‐looking guidance on future research for biomarker‐driven precision medicine in DKD.
- 19 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 2582-2593
Open AccessDiabetic kidney disease, biomarkers, and finerenone
Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals with DKD. While the standard treatment approach incorporating renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduces the risk for kidney disease progression and CVD, the high residual risk that persists despite these treatments underscores the need for novel therapies for DKD. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), is a proven therapeutic option for DKD that targets inflammatory and fibrotic pathways involved in its progression. Furthermore, finerenone has been evaluated for DKD outcomes in phase 3 clinical trials, has a favourable side effect profile compared to steroidal MRAs, reduces the risks of major kidney and CVD outcomes in clinical trials when used with RAAS blockers, and is the only MRA specifically approved for DKD and recommended for DKD in treatment guidelines. The integration of novel biomarkers of CKD and CVD into the clinical management of DKD may improve early identification of at‐risk individuals and allow for patient‐specific therapeutic strategies. This review provides a brief overview of the pathogenesis of DKD and the role of mineralocorticoid receptor activation in DKD pathobiology, summarises the role of finerenone in the treatment paradigm of DKD, evaluates current and emerging biomarkers of DKD and finerenone's impact on these biomarkers, and provides forward‐looking guidance on future research for biomarker‐driven precision medicine in DKD.
- 20 February 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 85 (3) , A16-A18
A Young Man With an Unusual Pulmonary-Renal Syndrome: A Quiz
- 20 February 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 85 (3) , A16-A18
A Young Man With an Unusual Pulmonary-Renal Syndrome: A Quiz
- 20 September 2024
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (1) , 43-52
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) globally and is associated with an increased risk of developing cardiovascular disease (CVD). DKD management requires a multipronged approach to decrease the progression of CKD and CVD. Mineralocorticoid receptor antagonists (MRAs) added to renin-angiotensin-aldosterone system blockade and sodium–glucose cotransporter 2 inhibitor therapy reduce the incidence of cardiovascular outcomes and progression of CKD. This review examines the cardiorenal benefits of MRAs and summarizes evidence on potential risks for acute kidney injury, hyperkalemia, and sexual dysfunction for steroidal and nonsteroidal MRAs.
- 20 September 2024
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (1) , 43-52
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) globally and is associated with an increased risk of developing cardiovascular disease (CVD). DKD management requires a multipronged approach to decrease the progression of CKD and CVD. Mineralocorticoid receptor antagonists (MRAs) added to renin-angiotensin-aldosterone system blockade and sodium–glucose cotransporter 2 inhibitor therapy reduce the incidence of cardiovascular outcomes and progression of CKD. This review examines the cardiorenal benefits of MRAs and summarizes evidence on potential risks for acute kidney injury, hyperkalemia, and sexual dysfunction for steroidal and nonsteroidal MRAs.
- Top Cited PapersOpen Access
- 25 March 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (5) , 771-782
SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for kidney failure and are a key component of guideline-directed therapy for CKD. While SGLT2 inhibitors’ ability to activate tubuloglomerular feedback and reduce hyperfiltration-mediated kidney injury is considered to be the central mechanism for kidney protection, recent data from experimental studies raise questions on the primacy of this mechanism. This review examines SGLT2 inhibitors’ role in tubuloglomerular feedback and summarizes emerging evidence on following of SGLT2 inhibitors’ other putative mechanisms for kidney protection: optimization of kidney's energy substrate utilization and delivery, regulation of autophagy and maintenance of cellular homeostasis, attenuation of sympathetic hyperactivity, and improvement in vascular health and microvascular function. It is imperative to examine the effect of SGLT2 inhibition on these different physiologic processes to help our understanding of mechanisms underpinning kidney protection with this important class of drugs.
- 25 March 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (5) , 771-782
Top Cited PapersOpen AccessSGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for kidney failure and are a key component of guideline-directed therapy for CKD. While SGLT2 inhibitors’ ability to activate tubuloglomerular feedback and reduce hyperfiltration-mediated kidney injury is considered to be the central mechanism for kidney protection, recent data from experimental studies raise questions on the primacy of this mechanism. This review examines SGLT2 inhibitors’ role in tubuloglomerular feedback and summarizes emerging evidence on following of SGLT2 inhibitors’ other putative mechanisms for kidney protection: optimization of kidney's energy substrate utilization and delivery, regulation of autophagy and maintenance of cellular homeostasis, attenuation of sympathetic hyperactivity, and improvement in vascular health and microvascular function. It is imperative to examine the effect of SGLT2 inhibition on these different physiologic processes to help our understanding of mechanisms underpinning kidney protection with this important class of drugs.
- Open Access
- 4 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0252679
End-stage kidney disease and COVID-19 in an urban safety-net hospital in Boston, Massachusetts
End-stage kidney disease (ESKD) patients are at a high risk for Coronavirus Disease 2019 (COVID-19). In this study, we compared characteristics and outcomes of ESKD and non-ESKD patients admitted with COVID-19 to a large safety-net hospital. We evaluated 759 adults (45 with ESKD) hospitalized with COVID-19 in Spring of 2020. We examined clinical characteristics, laboratory measures and clinical outcomes. Logistic regression analyses were performed to investigate the associations between ESKD status and outcomes. 73% of ESKD and 47% of non-ESKD patients identified as Black (p = 0.002). ESKD patients were older and had higher rates of comorbidities. Admission ferritin was approximately 6-fold higher in ESKD patients. During hospitalization, the rise in white blood cell count, lactate dehydrogenase, ferritin and C-reactive protein, and the decrease in platelet count and serum albumin were all significantly greater in ESKD patients. The in-hospital mortality was higher for ESKD [18% vs. 10%; multivariable adjusted odds ratio 1.5 (95% CI, 0.48–4.70)], but this did not reach statistical significance. Among hospitalized COVID-19 patients, ESKD patients had more co-morbidities and more robust inflammatory response than non-ESKD patients. The odds ratio point estimate for death was higher in ESKD patients, but the difference did not reach statistical significance.
- 4 June 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0252679
Open AccessEnd-stage kidney disease and COVID-19 in an urban safety-net hospital in Boston, Massachusetts
End-stage kidney disease (ESKD) patients are at a high risk for Coronavirus Disease 2019 (COVID-19). In this study, we compared characteristics and outcomes of ESKD and non-ESKD patients admitted with COVID-19 to a large safety-net hospital. We evaluated 759 adults (45 with ESKD) hospitalized with COVID-19 in Spring of 2020. We examined clinical characteristics, laboratory measures and clinical outcomes. Logistic regression analyses were performed to investigate the associations between ESKD status and outcomes. 73% of ESKD and 47% of non-ESKD patients identified as Black (p = 0.002). ESKD patients were older and had higher rates of comorbidities. Admission ferritin was approximately 6-fold higher in ESKD patients. During hospitalization, the rise in white blood cell count, lactate dehydrogenase, ferritin and C-reactive protein, and the decrease in platelet count and serum albumin were all significantly greater in ESKD patients. The in-hospital mortality was higher for ESKD [18% vs. 10%; multivariable adjusted odds ratio 1.5 (95% CI, 0.48–4.70)], but this did not reach statistical significance. Among hospitalized COVID-19 patients, ESKD patients had more co-morbidities and more robust inflammatory response than non-ESKD patients. The odds ratio point estimate for death was higher in ESKD patients, but the difference did not reach statistical significance.
- 15 April 2021
- Published by Agricultural Research Communication Center in Legume Research - An International Journal
- Vol. 45 (Of) , 1440-1444
Crop Productivity Enhancement under Soybean Based Cropping System through Harvested Rain Water in Malwa Region
Background: Rainwater harvesting is commonly practiced in areas, where the rainfall is insufficient for crop growing. Due to the intermittent nature of run-off events, it is necessary to store the maximum possible amount of rainwater during the rainy season so that it may be used as irrigation to enhance the crop productivity and farm income under soybean based cropping system. Methods: A study was carried out during 2018-2019 in Indore district of Malwa region. Rainwater harvesting tanks at on station (42×21×2.4m) and on farm (15×11×4m) were constructed for irrigation water availability. Provision of water harvesting tank increased the irrigation water availability (1781m3 and 630m3 respectively) and stored water was managed through various irrigation systems viz. rain gun, drip and flood. Result: It was resulted that the provision of water harvesting tanks enhanced the crop productivity and farm income under soybean based cropping system. Availability of irrigation encouraged the farmers to diversify the cropping pattern (soybean-chickpea, soybean -wheat). It is also clear from the study that even with smaller storage tank and through conjunctive use of ground (1164.2m3) and surface water (596m3), multiple crops (Soybean, potato, sweet corn, chickpea, onion, garlic etc.) can be grown. Soybean-Chickpea cropping system at station gave the net return of 70976 Rs/ha with B: C ratio of 3.15. Soybean-Wheat cropping system at farm gave the net return of 119000 Rs/ha with B:C ratio of 3.38.
- 15 April 2021
- Published by Agricultural Research Communication Center in Legume Research - An International Journal
- Vol. 45 (Of) , 1440-1444
Crop Productivity Enhancement under Soybean Based Cropping System through Harvested Rain Water in Malwa Region
Background: Rainwater harvesting is commonly practiced in areas, where the rainfall is insufficient for crop growing. Due to the intermittent nature of run-off events, it is necessary to store the maximum possible amount of rainwater during the rainy season so that it may be used as irrigation to enhance the crop productivity and farm income under soybean based cropping system. Methods: A study was carried out during 2018-2019 in Indore district of Malwa region. Rainwater harvesting tanks at on station (42×21×2.4m) and on farm (15×11×4m) were constructed for irrigation water availability. Provision of water harvesting tank increased the irrigation water availability (1781m3 and 630m3 respectively) and stored water was managed through various irrigation systems viz. rain gun, drip and flood. Result: It was resulted that the provision of water harvesting tanks enhanced the crop productivity and farm income under soybean based cropping system. Availability of irrigation encouraged the farmers to diversify the cropping pattern (soybean-chickpea, soybean -wheat). It is also clear from the study that even with smaller storage tank and through conjunctive use of ground (1164.2m3) and surface water (596m3), multiple crops (Soybean, potato, sweet corn, chickpea, onion, garlic etc.) can be grown. Soybean-Chickpea cropping system at station gave the net return of 70976 Rs/ha with B: C ratio of 3.15. Soybean-Wheat cropping system at farm gave the net return of 119000 Rs/ha with B:C ratio of 3.38.
- Top Cited Papers
- 1 December 2020
- Published by Elsevier in Primary Care: Clinics in Office Practice
- Vol. 47 (4) , 645-659
Diabetic Kidney Disease
- 1 December 2020
- Published by Elsevier in Primary Care: Clinics in Office Practice
- Vol. 47 (4) , 645-659
Top Cited PapersDiabetic Kidney Disease
- 1 June 2020
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 31 (6) , 391-393
CREDENCE: Significant Victory for Diabetic Kidney Disease
- 1 June 2020
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 31 (6) , 391-393
CREDENCE: Significant Victory for Diabetic Kidney Disease
- Open Access
- 1 September 2019
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 41 (3) , 312-314
Dialyzer reuse: is it safe and worth it?
Dialyzer reuse involves a complicated multistep process that includes rinsing, cleaning, performance testing, and disinfection of dialyzers prior to reuse. The process requires the use of cleaning and germicidal agents that are potentially toxic, and accidental contact with these agents may expose both patients and dialysis staff to health hazards.1,7-9 There are also reports of Gram-negative bacteremia outbreaks from the break-down in infection-control systems,10-12 and even a low-level exposure to toxins and microbiological contamination may contribute to chronic inflammation. Despite these potential risks, there are no randomized-controlled trials comparing single-use and reuse practices, and the evidence from observational studies are inconsistent.6,13 There is also a concern for conflicts of interest as studies sponsored by disinfectant manufacturers tend to show single-use and reuse practices having similar health outcomes while those sponsored by dialyzer manufacturers are more prone to show reduced risk with single-use.13,14 Notwithstanding the available evidence, given the 50 years of clinical experience with dialyzer reuse, there is a general agreement that the reuse process is likely safe when there is a strict adherence to the standards set by the Association for the Advancement of Medical Instrumentation (AAMI).15
- 1 September 2019
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 41 (3) , 312-314
Open AccessDialyzer reuse: is it safe and worth it?
Dialyzer reuse involves a complicated multistep process that includes rinsing, cleaning, performance testing, and disinfection of dialyzers prior to reuse. The process requires the use of cleaning and germicidal agents that are potentially toxic, and accidental contact with these agents may expose both patients and dialysis staff to health hazards.1,7-9 There are also reports of Gram-negative bacteremia outbreaks from the break-down in infection-control systems,10-12 and even a low-level exposure to toxins and microbiological contamination may contribute to chronic inflammation. Despite these potential risks, there are no randomized-controlled trials comparing single-use and reuse practices, and the evidence from observational studies are inconsistent.6,13 There is also a concern for conflicts of interest as studies sponsored by disinfectant manufacturers tend to show single-use and reuse practices having similar health outcomes while those sponsored by dialyzer manufacturers are more prone to show reduced risk with single-use.13,14 Notwithstanding the available evidence, given the 50 years of clinical experience with dialyzer reuse, there is a general agreement that the reuse process is likely safe when there is a strict adherence to the standards set by the Association for the Advancement of Medical Instrumentation (AAMI).15